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THE ASSESSMENT OF THE INFLUENCE OF AN
EDUCATIONAL INTERVENTION ON PATIENT
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RELATED QUALITY OF LIFE (HRQOL) AND
MORTALITY USING A TIME-TO-EVENT
SURVIVAL ANALYSIS IN PATIENTS WITH 
HEART FAILURE
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1McMaster University, London, ON, Canada; 2London Health
Sciences Centre, London, ON, Canada
OBJECTIVES: Patients with HF can suffer from poor
HRQoL particularly as their disease progresses. We
wanted to determine whether HRQoL and mortality dif-
ferences existed between patients following an interven-
tion. We deﬁned an event as either death or a drop from
baseline of at least 10 points in the PCS or MCS summary
scales of the SF-36 that was sustained on at least 2 con-
secutive intervals with no recovery prior to study termi-
nation. METHODS: This was an RCT (n = 134) with
HRQoL collection from baseline every 3 months to 1
year. All data collection and outcomes assessment were
done by study personnel who were blinded to patient
treatment allocation. Complete SF-36 data were available
on 114 patients. We did a Cox regression time-to-event
survival analysis adjusting for Arm. RESULTS: Accord-
ing to our deﬁnition of events 14.9% of patients had a
PCS event and 16.7% of patients had an MCS event.
There was no signiﬁcant effect of Arm. CONCLUSIONS:
A 10-point drop in the PCS or MCS can be considered to
be a minimal clinically important difference in patients
with a sustained drop indicating no response to the inter-
vention. The analytic techniques we used expand the
interpretability of HRQoL changes and incorporate 
clinical outcomes.
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POLISH SETTING
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OBJECTIVE: Although there is no ﬁnal agreement on
how willingness to pay (WTP) should be measured, 
it is increasingly used to value future health beneﬁts. 
The objective is to measure the ﬁnancial value of po-
tential health beneﬁts from antihypertensive treatment.
METHODS: The study was carried out in 103 hyperten-
sive patients in 3 centres in Poland. The WTP for theo-
retical antihypertensive agent (drug A) was measured
assuming that it would reduce the risk of ischemic heart
disease and strokes in the future. Patients were able to
choose the treatment or non-treatment option, data
obtained were conﬁdential. Three types of potential ben-
eﬁts from the new healthcare intervention were measured:
patient beneﬁts, insurance/option value and altruistic
value. RESULTS: The average WTP was €14,47 in terms
of drug’s price (patient beneﬁt), €3,16 as an insurance
premium (private beneﬁt) and €1,16 in additional taxes
(societal beneﬁt, all on monthly bases). Differences 
due to the regional level of development (wealth) were
observed. A strong correlation between individual income
and WTP was detected. The correlation between WTP
and a level of education and occupational status is
weaker. CONCLUSION: Patients are willing to pay more
then twice as much as the average price of a drug avail-
able on the market, (if not reimbursed) and 3.7 times the
amount of patient co-payment (if the drug is reimbursed).
Patients are willing to allocate a substantial part of their
income to avoid the complications of hypertension.
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COMPETITORS:THE STATINS
Esposito D
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OBJECTIVES: Many prescription drug markets are
inhabited by multiple patented drugs that perform similar
functions at different effectiveness levels without generic
competition. Little is known about the inﬂuence of drug
beneﬁts on drug choice in these markets. This paper
employs a multinomial logit regression to estimate 
the inﬂuence of copayments on demand for statins for
patients diagnosed with coronary heart disease (CHD).
METHODS: Patients selected for inclusion in the study
(N = 36,135) from the MarketScan Commercial Claims
and Encounters database were required to have an ICD-
9 diagnosis of CHD, use one of ﬁve statins (atorvastatin,
ﬂuvastatin, lovastatin, pravastatin, or simvastatin), and
be continuously enrolled in an identiﬁed health plan. To
estimate the inﬂuence of health plan beneﬁts on usage,
the average copayment for each patient’s statin over his
relevant therapy period was calculated relative to pravas-
tatin. Other explanatory variables used to control for
variation in statin choice included demographic factors,
clinical comorbidities, insurance type, and a proxy for
primary CHD prevention. RESULTS: Most patients in
the sample are treated with atorvastatin (N = 13,162) or
simvastatin (N = 12,863). The copayment of the patient’s
statin of choice has a highly signiﬁcant inﬂuence on statin
choice. An increase in the patient’s copayment relative to
the copayment of pravastatin, over the patient’s therapy
period, decreases the likelihood of receiving that statin by
as much as 84% (lovastatin), and as little as 11% (ator-
vastatin). CONCLUSION: Findings suggest that insurers
can inﬂuence a patient’s choice of one drug over another
by varying a patient’s copayment level. Moreover, results
